Francesc Jiménez-Altayó

Francesc Jiménez-Altayó

   

Francesc Jiménez-Altayó

Teléfono:

Email:
Francesc.Jimenez@uab.cat

Dirección:


Dr. Francesc Jiménez-Altayó is the coordinator of the Cerebral and peripheral vascular disease laboratory:

 

 

Group members:

  • Belén Pérez Fernandez (Researcher)
  • Maria Isabel Delgado Calvarro (Lab technician)
  • Andrea Diaz Pérez (PhD student)
  • Julia Bajsert (PhD student)

 

Strategic objective:
To understand the contribution of cerebral and systemic circulation in cardiovascular and brain disorders, and to search for new therapeutic targets
 

Main research lines:
1. Cerebrovascular alterations in ischemic stroke and pharmacological brain neuroprotection
2. Cerebral and peripheral vascular dysfunction in rare diseases

1. An Imidazoline 2 Receptor Ligand Relaxes Mouse Aorta via Off-Target Mechanisms Resistant to Aging. Jiménez-Altayó F, Cabrera A, Bagán A, Giménez-Llort L, D'Ocon P, Pérez B, Pallàs M, Escolano C. Front Pharmacol. 2022 May 12;13:826837. doi: 10.3389/fphar.2022.826837.

2. Plasma sICAM-1 as a Biomarker of Carotid Plaque Inflammation in Patients with a Recent Ischemic Stroke. Puig N, Camps-Renom P, Camacho M, Aguilera-Simón A, Jiménez-Altayó F, Fernández-León A, Marín R, Martí-Fàbregas J, Sánchez-Quesada JL, Jiménez-Xarrié E, Benitez S. Transl Stroke Res. 2022 Mar 2. doi: 10.1007/s12975-022-01002-x.

3. Arachnoid membrane as a source of sphingosine-1-phosphate that regulates mouse middle cerebral artery tone. Jiménez-Altayó F, Marzi J, Galan M, Dantas AP, Ortega M, Rojas S, Egea G, Schenke-Layland K, Jiménez-Xarrié E, Planas AM. J Cereb Blood Flow Metab. 2022 Jan;42(1):162-174. doi: 10.1177/0271678X211033362.

4. Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome. Arce C, Rodríguez-Rovira I, De Rycke K, Durán K, Campuzano V, Fabregat I, Jiménez-Altayó F, Berraondo P, Egea G. Arterioscler Thromb Vasc Biol. 2021 Sep;41(9):e440-e452. doi: 10.1161/ATVBAHA.121.316496.

5. Sex-Dependent End-of-Life Mental and Vascular Scenarios for Compensatory Mechanisms in Mice with Normal and AD-Neurodegenerative Aging. Muntsant A, Jiménez-Altayó F, Puertas-Umbert L, Jiménez-Xarrie E, Vila E, Giménez-Llort L. Biomedicines. 2021 Jan 24;9(2):111. doi: 10.3390/biomedicines9020111.

6. The homeostatic role of hydrogen peroxide, superoxide anion and nitric oxide in the vasculature. Costa TJ, Barros PR, Arce C, Santos JD, da Silva-Neto J, Egea G, Dantas AP, Tostes RC, Jiménez-Altayó F. Free Radic Biol Med. 2021 Jan;162:615-635. doi: 10.1016/j.freeradbiomed.2020.11.021.

7. Stenosis coexists with compromised α1-adrenergic contractions in the ascending aorta of a mouse model of Williams-Beuren syndrome. Jiménez-Altayó F, Ortiz-Romero P, Puertas-Umbert L, Dantas AP, Pérez B, Vila E, D'Ocon P, Campuzano V. Sci Rep. 2020 Jan 21;10(1):889. doi: 10.1038/s41598-020-57803-3.

8. Uric acid treatment after stroke modulates the Krüppel-like factor 2-VEGF-A axis to protect brain endothelial cell functions: Impact of hypertension. Vila E, Solé M, Masip N, Puertas-Umbert L, Amaro S, Dantas AP, Unzeta M, D'Ocon P, Planas AM, Chamorro Á, Jiménez-Altayó F. Biochem Pharmacol. 2019 Jun;164:115-128. doi: 10.1016/j.bcp.2019.04.002. Epub 2019 Apr 4.

9. Uric Acid Treatment After Stroke Prevents Long-Term Middle Cerebral Artery Remodelling and Attenuates Brain Damage in Spontaneously Hypertensive Rats. Jiménez-Xarrié E, Pérez B, Dantas AP, Puertas-Umbert L, Martí-Fabregas J, Chamorro Á, Planas AM, Vila E, Jiménez-Altayó F. Transl Stroke Res. 2020 Dec;11(6):1332-1347. doi: 10.1007/s12975-018-0661-8.

10. CD69 Plays a Beneficial Role in Ischemic Stroke by Dampening Endothelial Activation. Brait VH, Miró-Mur F, Pérez-de-Puig I, Notario L, Hurtado B, Pedragosa J, Gallizioli M, Jiménez-Altayó F, Arbaizar-Rovirosa M, Otxoa-de-Amezaga A, Monteagudo J, Ferrer-Ferrer M, de la Rosa X, Bonfill-Teixidor E, Salas-Perdomo A, Hernández-Vidal A, Garcia-de-Frutos P, Lauzurica P, Planas AM. Circ Res. 2019 Jan 18;124(2):279-291. doi: 10.1161/CIRCRESAHA.118.313818.

See all publications

Instituto de Neurociencias

Administració

Tel: 93 581 3861
Fax: +34 93 581 3327
i.neurociencies@uab.cat

Comunicació

Tel: 93 581 33 27
comunicacio.inc@uab.cat

Facultad de Medicina. Edificio M-1
Calle de la Vinya - Campus de la UAB · 08193
Bellaterra (Cerdanyola del Vallès) · Barcelona